1. Ross, C. A. & Tabrizi, S. J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83–98 (2011).

2. Bates, G. P. et al. Huntington disease. Nat. Rev. Dis. Prim. 1, 15005 (2015).

3. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72, 971–983 (1993).

4. Zuccato, C., Valenza, M. & Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol. Rev. 90, 905–981 (2010).

5. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101, 57–66 (2000).

6. Boudreau, R. L. et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol. Ther. 17, 1053–1063 (2009).

7. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820–5825 (2005).

8. Kordasiewicz, HollyB. et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74, 1031–1044 (2012).

9. Stanek, L. M. et al. Silencing mutant huntingtin by AAV-mediated RNAi ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum. Gene Ther. 25, 461–74 (2014).

10. Grondin, R. et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197–1209 (2012).

11. McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as apotential therapy for Huntington’s disease. Mol. Ther. 19, 2152–2162 (2011).

12. Stiles, D. K. et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp. Neurol. 233, 463–471 (2012).

13. Duyao, M. P. et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 269, 407–410 (1995).

14. Nasir, J. et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81, 811–823 (1995).

15. Dragatsis, I., Levine, M. S. & Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300–306 (2000).

16. Arteaga-Bracho, E. E. et al. Postnatal and adult consequences of loss of huntingtin during development:implications for Huntington’s disease. Neurobiol. Dis. 96, 144–155 (2016).

17. Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359–3364 (2016).

18. Dietrich, P., Johnson, I. M., Alli, S. & Dragatsis, I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 13, e1006846 (2017).

19. Lopes, F. et al. Identification of novel genetic causes of Rett syndrome-like phenotypes. J. Med. Genet. 53, 190–199 (2016).

20. Monteys, A. M., Wilson, M. J., Boudreau, R. L., Spengler, R. M. & Davidson, B. L. Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. Mol. Ther. Nucleic Acids 4, e234 (2015).

21. Pfister, E. L. et al. Five siRNAs targeting three SNPs in huntingtin may provide therapy for three-quarters of Huntington’s disease patients. Curr. Biol. 19, 774–778 (2009).

22. Southwell, A. L. et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol. Ther. 22, 2093–2106 (2014).

23. Gagnon, K. T. et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166–10178 (2010).

24. Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895–908 (2012).

25. Reiter, F., Wienerroither, S. & Stark, A. Combinatorial function of transcription factors and cofactors. Curr. Opin. Genet. Dev. 43, 73–81 (2017).

26. Marti, E. RNA toxicity induced by expanded CAG repeats in Huntington’s disease. Brain Pathol. 26, 779–786 (2016).

27. Garriga-Canut, M. et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl Acad. Sci. USA 109, 3136–3145 (2012).

28. Agustin-Pavon, C., Mielcarek, M., Garriga-Canut, M. & Isalan, M. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol. Neurodegener. 11, 64 (2016).

29. Gersbach, C. A. & Perez-Pinera, P. Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opin. Ther. Targets 18, 835–839 (2014).

30. Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509–1512 (2009).

31. Thakore, P. I., Black, J. B., Hilton, I. B. & Gersbach, C. A. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat. Methods 13, 127–137 (2016).

32. Margolin, J. F. et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl Acad. Sci. USA 91, 4509–4513 (1994).

33. Landwehrmeyer, G. B. et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease. Mov. Disord. Clin. Pract. 4, 212–224 (2017).

34. Consortium, H. Di Developmental alterations in Huntington’s disease neural cells and pharmacological rescue in cells and mice. Nat. Neurosci. 20, 648–660 (2017).

35. Mattis, V. B. et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet. 24, 3257–3271 (2015).

36. Menalled, L. et al. Systematic behavioral evaluation of Huntington’s disease transgenic and knock-in mouse models. Neurobiol. Dis. 35, 319–336 (2009).

37. Heikkinen, T. et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS ONE 7, e50717 (2012).

38. Carty, N. et al. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington’s disease: an in vivo high-content imaging study. PLoS ONE 10, e0123527 (2015).

39. Menalled, L. B. et al. Comprehensive behavioral and molecular characterization of a new knock-in mousemodel of Huntington’s Disease: zQ175. PLoS ONE 7, e49838 (2012).

40. Plotkin, J. L. & Surmeier, D. J. Corticostriatal synaptic adaptations in Huntington’s disease. Curr. Opin. Neurobiol. 33, 53–62 (2015).

41. Russell, D. S. et al. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging. Neurology 86, 748–754 (2016).

42. Niccolini, F. et al. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. J. Neurol. Neurosurg. Psychiatry 89, 185–196 (2018).

43. Haggkvist, J. et al. Longitudinal small-animal PET imaging of the zQ175 mouse model of Huntington disease shows in vivo changes of molecular targets in the striatum and cerebral cortex. J. Nucl. Med. 58, 617–622 (2017).

44. Monod, J., Wyman, J. & Changeux, J. P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12, 88–118 (1965).

45. Pavletich, N. P. & Pabo, C. O. Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science 252, 809–817 (1991).

46. Nekludova, L. & Pabo, C. O. Distinctive DNA conformation with enlarged major groove is found in Zn-finger-DNA and other protein-DNA complexes. Proc. Natl Acad. Sci. USA 91, 6948–6952 (1994).

47. Mirny, L. A. Nucleosome-mediated cooperativity between transcription factors. Proc. Natl Acad. Sci. USA 107, 22534–22539 (2010).

48. Iyengar, S. & Farnham, P. J. KAP1 protein: an enigmatic master regulator of the genome. J. Biol. Chem. 286, 26267–26276 (2011).

49. Lupo, A. et al. KRAB-zinc finger proteins: a repressor family displaying multiple biological functions. Curr. Genom. 14, 268–278 (2013).

50. Hinde, E., Cardarelli, F. & Gratton, E. Spatiotemporal regulation of oligomerization and dynamics in live cells. Sci. Rep. 5, 12001 (2015).

51. Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA 110, 2366–2370 (2013).

52. Banez-Coronel, M. et al. RAN translation in Huntington disease. Neuron 88, 667–677 (2015).

53. Capelli, P., Pivetta, C., Soledad Esposito, M. & Arber, S. Locomotor speed control circuits in the caudal brainstem. Nature 551, 373–377 (2017).

54. Wang, N. et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat. Med. 20, 536–541 (2014).

55. Indersmitten, T., Tran, C. H., Cepeda, C. & Levine, M. S. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington’s disease. J. Neurophysiol. 113, 2953–2966 (2015).

56. Datson, N. A. et al. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE 12, e0171127 (2017).

57. Russell, D. S. et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol. 71, 1520–1528 (2014).

58. Wilson, H. et al. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers. J. Neurol. Sci. 368, 243–248 (2016).

59. Bankiewicz, K. S. et al. AAV viral vector delivery to the brain by shape-conforming MR-guided infusions. J. Control Release 240, 434–442 (2016).

60. Waldvogel, H. J., Kim, E. H., Tippett, L. J., Vonsattel, J. P. & Faull, R. L. The neuropathology of Huntington’s disease. Curr. Top. Behav. Neurosci. 22, 33–80 (2015).

61. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636–646 (2010).

62. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471 (1998).

63. Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum. Mol. Genet. 9, 2799–2809 (2000).

64. Bradley, C. K. et al. Derivation of Huntington’s disease-affected human embryonic stem cell lines. Stem Cells Dev. 20, 495–502 (2011).

65. Morlan, J., Baker, J. & Sinicropi, D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PloS ONE 4, e4584 (2009).

66. Latorra, D., Campbell, K., Wolter, A. & Hurley, J. M. Enhanced allele-specific PCR discrimination in SNP genotyping using 3’ locked nucleic acid (LNA) primers. Hum. Mutat. 22, 79–85 (2003).

67. You, Y., Moreira, B. G., Behlke, M. A. & Owczarzy, R. Design of LNA probes that improve mismatch discrimination. Nucleic Acids Res. 34, e60 (2006).

68. Plautz, S. A., Boanca, G., Riethoven, J. J. & Pannier, A. K. Microarray analysis of gene expression profiles in cells transfected with nonviral vectors. Mol. Ther. 19, 2144–2151 (2011).

69. White, J. K. et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat. Genet. 17, 404–410 (1997).

70. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996).

71. Minderer, M. et al. Chronic imaging of cortical sensory map dynamics using a genetically encoded calcium indicator. J. Physiol. 590, 99–107 (2012).

72. Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973–985 (1999).

73. Langer, O. et al. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C] raclopride from [11C] methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal of the International Isotope Society 42, 1183–1193 (1999).

74. Nagy, K. et al. Performance evaluation of the small-animal nanoScan PET/MRI system. J. Nucl. Med. 54, 1825–1832 (2013).